Cell & Gene Therapy Manufacturing Services Market Predicted to reach $11.5 billion by 2027

The global Cell Gene Therapy Manufacturing Services Market in terms of revenue was estimated to be worth $5.1 billion in 2022 and is poised to reach $11.5 billion by 2027, growing at a CAGR of 17.5% from 2022 to 2027.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441

The gene therapy segment accounted for the second largest share of the type segment 2021.

In 2021, gene therapy accounted for the second largest share of the cell gene therapy manufacturing services market. Several gene therapy technologies, such as vector design, DNA vaccine design, and gene-delivery vehicles, are currently under study, and very few are marketed. The growing prevalence of hereditary diseases, as well as acute and chronic diseases, is resulting in an increase in the demand for gene therapy.

Oncology accounted for the largest share of the indication segment in 2021.

The oncology diseases segment accounted for the largest share of the cell gene therapy manufacturing services market in 2021. The large share of this segment can be attributed to the high number of clinical trials and the rising number of cancer cases worldwide. According to data by GLOBOCAN, in 2020, the number of cancer cases and deaths increased to 19.3 million and 10 million, respectively, from 18.1 million new cases and 9.6 million deaths in 2018.

The clinical manufacturing segment accounted for the largest share of the application segment in 2021.

The clinical manufacturing application segment accounted for the largest share of the cell gene therapy manufacturing services market in 2021. Cellular gene therapy-related research and development worldwide continue to grow rapidly, with several products advancing in clinical development. Thus, increase in the number of clinical trials for the development of cell gene therapies is fueling the growth of this segment.

Pharmaceutical biotechnology companies accounted for the largest end user segment in 2021.

Pharmaceutical biotechnology companies form the largest end-user segment of the cell gene therapy manufacturing services market. The large share of this segment can be attributed to the increasing expenditure on RD by pharmaceutical biotechnology companies, increasing collaborations between pharmaceutical and biotechnology companies for the launch of new products, and the growing number of cell gene therapies in the RD pipeline.

The Asia Pacific region is the fastest-growing region of the cell gene therapy manufacturing services market in 2021.

In 2021, the Asia Pacific region of the cell gene therapy manufacturing services market grew at the fastest CAGR region during the forecast period. The factors such as growing research in the life sciences sector along with increasing outsourcing trend for drug discovery services is expected to fuel the market growth in this region.

Some of the prominent players in the Cell gene therapy manufacturing services market are Lonza (Switzerland), Catalent (US), Thermo Fisher Scientific (US), Charles River Laboratories (US WuXi AppTec (China), Merck KGaA (Germany), Takara Bio Inc. (Japan), Nikon Corporation (Japan), FUJIFILM Holdings Corporation (Japan), Oxford Biomedica plc (UK), and Cell and Gene Therapy Catapult (UK).

https://www.marketsandmarkets.com/Market-Reports/cell-gene-therapy-manufacturing-services-market-180609441.html